FDA Launches TEMPO Pilot to Test AI‑Enabled Health Devices Before Formal Authorization
What Happened — The FDA’s Technology‑Enabled Meaningful Patient Outcomes (TEMPO) pilot selected four manufacturers to field AI‑driven tools for diabetes, hypertension, and mental‑health care. The program lets these devices reach patients under enforcement discretion while the agency gathers real‑world performance data.
Why It Matters for Trust & Control Assurance
- Demonstrates the need for continuous AI‑model governance — organizations must document design, validation, and post‑deployment monitoring to satisfy regulators and auditors.
- Highlights that traditional cybersecurity controls still apply to AI‑enabled medical devices, requiring evidence of secure development and operational oversight.
- Provides a concrete use‑case for mapping AI‑risk controls to a single control objective that satisfies multiple frameworks (e.g., NIST AI RMF, ISO 42001).
Who Is Affected – Health‑care providers, medical‑device manufacturers, and health‑tech SaaS vendors delivering AI‑based diagnostics or therapy.
Recommended Actions – Align your AI‑model risk management program with the FDA’s “enforcement discretion” expectations: inventory AI models, define validation metrics, capture real‑world usage logs, and maintain auditable evidence of security controls. Source: DataBreachToday
Technical Notes – The pilot covers AI voice therapy, AI‑driven blood‑pressure medication management, and AI glucose‑insight tools. No specific CVEs are cited; the focus is regulatory oversight of generative AI in medical devices. Source: same